WHAT IS CLAIMED IS:

- 1. A liposome preparation that comprises an SDI molecule.
- 5 2. The liposome preparation of claim 1 comprises:
 - (a) a mixture of a polycationic and a neutral lipid; and
 - (b) an SDI molecule selected from the group consisting of SDI-1 protein and an SDI-1-encoding nucleic acid molecule.

10

- 3. The liposome preparation of claim 2, wherein said polycationic lipid is 2,3-dioleyloxy-N-[2(sperminecarboxamido)-ethyl]-N,N-dimethyl-1-propanaminium-trifluoroacetate (DOSPA).
- 15 4. The liposome preparation of claim 2, wherein said neutral lipid is dioleolyphosphatidylethanolamine (DOPE).
 - 5. The liposome preparation of claim 3, wherein said neutral lipid is dioleolyphosphatidylethanolamine (DOPE).

20

- 6. The liposome preparation of claim 5, wherein said polycationic and a neutral lipid are present in said liposome in a 3:1 (w/w) mixture.
- 7. The liposome preparation of claim 1, wherein said SDI molecule is an SDI-1 protein.
 - 8. The liposome preparation of claim 1, wherein said SDI molecule is an SDI-1-encoding nucleic acid molecule.

30

9. The liposome preparation of claim 8, wherein said SDI-1-encoding nucleic acid molecule is operably linked to a promoter, but is separated from said operably linked promoter by a non-translated intervening polynucleotide.

35

5

10

20

- 10. The liposome preparation of claim 8, wherein said SDI-1-encoding nucleic acid molecule is operably linked to a promoter, and contains a non-translated intervening polynucleotide which separates a region of said SDI-1-encoding nucleic acid that encodes part of SDI-1 from a region of said SDI-1-encoding nucleic acid that encodes a different part of SDI-1.
- 11. A method for preparing a liposome preparation of SDI molecules which comprises incubating liposomes that comprise a mixture of a polycationic and a neutral lipid with an SDI molecule selected from the group consisting of SDI-1 protein and an SDI-1-encoding nucleic acid molecule.
- 12. A method of providing an SDI molecule to a cell which 15 comprises:
 - (A) contacting said cell with a liposome preparation that comprises a mixture of a polycationic and a neutral lipid and an SDI molecule selected from the group consisting of SDI-1 protein and an SDI-1-encoding nucleic acid molecule; and
 - (B) permitting the intracellular delivery of said SDI-1 molecule of said liposome preparation.
- 13. An SDI-1-encoding nucleic acid molecule, operably linked to a promoter, but separated from said operably linked promoter by a non-translated intervening polynucleotide.
 - 14. A method of transcribing an SDI-1-encoding nucleic acid molecule which comprises:
- 30 (A) providing to a cell said SDI-1-encoding nucleic acid molecule, operably linked to a promoter, but separated from said operably linked promoter by a non-translated intervening polynucleotide; and
- (B) permitting said promoter to mediate the transcription of said SDI-1-encoding nucleic acid molecule.

5

- 15. A nucleic acid molecule that encodes SDI-1, a fragment of SDI-1, an SDI-1 fusion protein or a mimetic or analog of SDI-1.
- 16. A protein or polypeptide capable of inhibiting DNA synthesis in a recipient cell, wherein said protein or polypeptide is SDI-1, a fragment of SDI-1, an SDI-1 fusion protein or a mimetic or analog of SDI-1.
- 17. A method for treating a disease of undesired cellular proliferation which comprises providing to a recipient a nucleic acid molecule that encodes SDI-1, a fragment of SDI-1, an SDI-1 fusion protein, an SDI-1 mimetic, or an analog of SDI-1.
- 18. A method for treating a disease of undesired cellular proliferation which comprises providing to a recipient a protein or polypeptide capable of inhibiting DNA synthesis in a recipient cell, wherein said protein or polypeptide is SDI-1, a fragment of SDI-1, an SDI-1 fusion protein or a mimetic or analog of SDI-1.
- 19. A method for treating a disease of undesired cellular quiescence which comprises providing to a recipient a nucleic acid molecule that encodes an inhibitor of SDI-1.
- 20. A method for treating a disease of undesired cellular quiescence which comprises providing to a recipient a protein, polypeptide, or organic molecule capable of inhibiting SDI-1.